Ahmed Obeidat, MD, PhD, Medical College of Wisconsin, Milwaukee, WI, is excited about promising clinical trials regarding multiple sclerosis (MS) treatment. The evolving therapeutic landscape in MS includes tackling the dysregulation of the immune system, demyelination of neurons, and neurotoxicity, through methods such as immunomodulation, remyelination and neuroprotection, respectively. Of these three approaches, only immunomodulation has effective therapies at present. Dr Obeidat discusses future potential avenues, such as combination therapy and anti-viral approaches, relating to the recent confirmatory data linking Epstein Barr virus to MS causation. Several Phase III clinical trials currently underway are investigating Bruton’s tyrosine kinase (BTK) inhibitors that are likely to have therapeutic effects directly in the central nervous system, unlike previous medication. Cellular therapies are also moving closer to becoming reality. This interview took place at the Consortium of Multiple Sclerosis Centers (CMSC) congress 2022 in Maryland.